博雅生物
(300294)
| 流通市值：159.14亿 | | | 总市值：159.14亿 |
| 流通股本：5.04亿 | | | 总股本：5.04亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,245,107,779.6 | 895,735,666.55 | 448,452,537.26 | 2,651,979,506.66 |
| 营业收入 | 1,245,107,779.6 | 895,735,666.55 | 448,452,537.26 | 2,651,979,506.66 |
| 二、营业总成本 | 853,438,255.57 | 590,060,239.82 | 301,267,242.96 | 2,087,581,221.28 |
| 营业成本 | 415,047,987.13 | 295,361,445.36 | 144,457,836.4 | 1,252,860,597.03 |
| 税金及附加 | 12,960,180.36 | 8,020,971.78 | 4,016,540.27 | 20,073,412.91 |
| 销售费用 | 273,785,234.14 | 192,731,269.38 | 104,036,460.15 | 582,589,429.72 |
| 管理费用 | 127,759,054.31 | 80,666,785.32 | 37,957,181.42 | 194,854,096.46 |
| 研发费用 | 47,378,915.31 | 30,323,589.35 | 19,006,039.85 | 67,696,290.28 |
| 财务费用 | -23,493,115.68 | -17,043,821.37 | -8,206,815.13 | -30,492,605.12 |
| 其中:利息费用 | 125,070.13 | 104,472.44 | 18,610.32 | 455,592.95 |
| 其中:利息收入 | 23,873,998.69 | 17,317,447.97 | 8,270,480.83 | 31,293,144.37 |
| 加:公允价值变动收益 | 60,816,469.74 | 39,088,022.83 | 18,515,926.66 | 85,735,257.45 |
| 加:投资收益 | 7,811,944.55 | 6,709,830.32 | 1,191,885.1 | 14,014,242.6 |
| 资产处置收益 | -302,546.14 | -125,108.14 | - | 1,299,836.17 |
| 资产减值损失(新) | 628,571.77 | -196,478.4 | 660,313.48 | -329,659,853 |
| 信用减值损失(新) | -2,906,848.49 | -5,830,411.4 | -1,685,231.72 | -2,456,983.7 |
| 其他收益 | 22,587,554.44 | 21,250,412.03 | 8,880,607.49 | 21,894,275.3 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 480,304,669.9 | 366,571,693.97 | 174,748,795.31 | 355,225,060.2 |
| 加:营业外收入 | 5,986,732.7 | 5,157,397.92 | 1,594,051.4 | 3,797,885.03 |
| 减:营业外支出 | 5,866,127.73 | 3,879,495.21 | 68,871.54 | 5,311,157.12 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 480,425,274.87 | 367,849,596.68 | 176,273,975.17 | 353,711,788.11 |
| 减:所得税费用 | 67,992,997.01 | 52,146,631.24 | 24,513,132.74 | 105,563,390.25 |
| 六、净利润 | 412,432,277.86 | 315,702,965.44 | 151,760,842.43 | 248,148,397.86 |
| 持续经营净利润 | 412,432,277.86 | 315,702,965.44 | 151,760,842.43 | 215,135,907.25 |
| 终止经营净利润 | - | - | - | 33,012,490.61 |
| 归属于母公司股东的净利润 | 412,703,629.27 | 315,970,311.01 | 152,024,886.81 | 237,465,593.87 |
| 少数股东损益 | -271,351.41 | -267,345.57 | -264,044.38 | 10,682,803.99 |
| (一)基本每股收益 | 0.82 | 0.63 | 0.3 | 0.47 |
| (二)稀释每股收益 | 0.82 | 0.63 | 0.3 | 0.47 |
| 九、综合收益总额 | 412,432,277.86 | 315,702,965.44 | 151,760,842.43 | 248,148,397.86 |
| 归属于母公司股东的综合收益总额 | 412,703,629.27 | 315,970,311.01 | 152,024,886.81 | 237,465,593.87 |
| 归属于少数股东的综合收益总额 | -271,351.41 | -267,345.57 | -264,044.38 | 10,682,803.99 |
| 公告日期 | 2024-10-25 | 2024-08-24 | 2024-04-24 | 2024-03-23 |
| 审计意见(境内) | | | | 标准无保留意见 |